Cargando...
Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2
Medical treatment has progressed significantly over the past decade towards achieving and maintaining clinical remission in patients with refractory ulcerative colitis (UC). Proposed mediators of inflammation in UC include pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α) and interl...
Guardado en:
| Publicado en: | World J Gastroenterol |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Baishideng Publishing Group Inc
2015
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4528020/ https://ncbi.nlm.nih.gov/pubmed/26269667 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v21.i29.8776 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|